Speaker Profile

President & CEO, Serimmune

Noah Nasser is Serimmune's Chief Executive Officer. With more than twenty-five years of experience in biotechnology, Noah brings a broad background in the development and commercialization of novel technology to advance human health. Noah joins Serimmune from San Diego biotechnology company, Human Longevity, Inc., a direct-to-consumer health screening organization combining proprietary imaging and genetic technologies, where he was chief commercial officer. Prior to Human Longevity, Noah was chief commercial officer at Counsyl, a market leading genetic testing laboratory focused on women's health applications, including non-invasive prenatal testing, expanded carrier screening and hereditary cancer screening. Noah led Counsyl's commercial team through its acquisition in 2018 by Myriad Genetics, Inc. He previously held senior leadership positions at San Diego-based biotechnology company AltheaDx, and San Carlos-based Verinata Health, a leader in non-invasive prenatal testing (NIPT), where he led his team through the company's acquisition by Illumina in 2013.

Applications of Functional Antibody Repertoire beyond Research
Serimmune has developed a novel technology for assessing personal immune response through antibody repertoires. We will describe the application of this technology in the clinical space for diagnosis of immune agents in diverse diseases and syndromes as well as how these data may lead to better health outcomes in the future.

 Session Abstract – PMWC 2022 Silicon Valley

Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.


  • 4th Generation Sequencing Technologies & Genome Mapping Systems
    - Barrett Bready, Nabsys
    - Alka Chaubey, Bionano Genomics
  • Long-Read Sequencing Technologies
    - Steve Turner, PacBio
  • Single Cell Genomics
    - Michael Schnall-Levin, 10x Genomics
  • Spatial Transcriptomics
    - Jason T. Gammack, Resolve Biosciences
  • Pathogen Identification
    Session Chair: Charles Chiu, UCSF
    - Todd Dickinson, Arc Bio
    - Philip Stevens, Noscendo
  • ML/AI for Diagnosis & Prognosis
    - Amrie Grammer, Ampel BioSolutions
  • Modern Technologies for Pathogen Identification + AI
    Session Chair: Sivan Bercovici, Karius Dx
  • Proteogenomics
    - Nigel Beard, Encodia
  • Advances Proteomics - Stratifying Cardiovascular Risk to Decrease Cost of Care
    Session Chair: Roy Smythe, SomaLogic
    - Matthias Kleinz, UPMC
  • Leveraging Immune System Diagnostics to Improve Disease Outcomes
    Session Chair: Kathy Kamath, Serimmune, Inc
    - Millennia Lytle, Mymee
    - Noah Nasser, Serimmune, Inc
  • Evolving Alzheimer’s Disease Therapeutics with Neuro Diagnostic Therapies
    Session Chair: Kevin Hrusovsky, Quanterix
    - Charlotte Teunissen, Amsterdam UMC
    - Henrik Zetterberg, University of Gothenburg
    - Nicholas Ashton, University of Gothenburg
  • PMWC Showcase (NCI)
    - Michael Cardone, Eutropics Pharmaceuticals
    - Robert Meltzer, Fluent BioSciences
    - Cynthia Taylor Lawley, Olink Proteomics
    - Brian McKelligon, Akoya Biosciences